Comparative Pharmacology
Head-to-head clinical analysis: CEFTAZIDIME IN DEXTROSE CONTAINER versus SEFFIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTAZIDIME IN DEXTROSE CONTAINER versus SEFFIN.
CEFTAZIDIME IN DEXTROSE CONTAINER vs SEFFIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftazidime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibition, leading to cell lysis and death.
SEFFIN is a brand name for cefazolin, a first-generation cephalosporin antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It is bactericidal against susceptible organisms.
1-2 g intravenously every 8 hours.
1-2 g IV/IM every 6-8 hours; maximum 8 g/day.
None Documented
None Documented
1.9 hours (normal renal function); prolonged to 22-30 hours in ESRD
Terminal elimination half-life is approximately 0.5-1 hour in adults with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Renal: 80-90% unchanged drug via glomerular filtration; biliary: <1%; fecal: <1%
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; minor biliary excretion (<5%) and fecal elimination.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic